Abstract: Diarun plus was evaluated for its therapeutic antihyperglycemic activity in streptozotocin-induced diabetes in animal models. It was effective in controlling hyperglycemic status in rats and mice. The drug (500 mg/kg) showed significant antidiabetic property as judged by serum glucose levels. However, it did not significantly influence the levels of serum insulin in both diabetic and normoglycemic rats. This is a promising drug to develop standardized phytomedicine for diabetes mellitus. The findings suggest that it can be considered as a therapeutic agent, wherever elevated glycemic status is observed.